ACTRIMS 2022 | Potential use of MRI sequencing in the clinical setting of MS
Raphael Schneider
• 2 Mar 2022
Raphael Schneider, MD, PhD, FRCPC, CIP, St. Michael’s Hospital, Toronto, Canada, speaks on the future use of MRI markers to further our understanding and clinical management of multiple sclerosis (MS) and radiologically isolated syndrome (RIS). The paramagnetic rim sign and central vein sign are emerging as promising markers for MS and Dr Schneider hopes 3 Tesla (T) and 7T MRIs can be used in a clinical setting to better understand the disease. This interview took place at the ACTRIMS Forum 2022 in West Palm Beach, Florida.
